SGRY: Jefferies Maintains Buy Rating, Raises Price Target May 2026

Jefferies maintained its Buy rating on Surgery Partners (SGRY) while raising its price target to $17 from $15. This analyst rating maintained reflects confidence in the healthcare facility operator’s growth trajectory. The stock trades at $14.59 with a market cap of $1.89 billion. Surgery Partners operates 126 surgical facilities across 31 states, including ambulatory surgery centers and surgical hospitals. The analyst rating maintained by Jefferies signals steady conviction despite recent market volatility affecting the sector.

Jefferies Maintains Buy Rating with Higher Price Target

Analyst Rating Maintained at Buy

Jefferies kept its Buy rating intact while raising the price target to $17 from $15, representing 16% upside from current levels. This analyst rating maintained demonstrates the firm’s continued belief in SGRY’s operational execution and market positioning. The $17 target reflects expectations for improved profitability and cash flow generation across the surgical facility network.

Price Target Implications

The raised price target suggests Jefferies sees meaningful value creation ahead. At $14.59, the stock trades below the new target, offering investors a potential entry point. The analyst rating maintained indicates no fundamental concerns despite broader healthcare sector headwinds affecting valuations across the industry.

Surgery Partners Financial Position and Meyka Grade

Strong Operational Metrics

Surgery Partners generated $26.05 in revenue per share trailing twelve months. The company maintains a solid current ratio of 1.86, indicating strong liquidity to fund operations and growth initiatives. Operating margins stand at 11.8%, showing the business model’s inherent profitability despite near-term earnings pressures from integration activities.

Meyka AI Stock Grade

Meyka AI rates SGRY with a grade of B+, reflecting solid fundamentals and growth potential. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The B+ rating suggests the stock offers reasonable risk-adjusted returns for investors seeking healthcare exposure. These grades are not guaranteed and we are not financial advisors.

Market Performance and Analyst Consensus

Recent Price Action

SGRY trades at $14.59, up 2.31% today but down 36.6% over the past year. The stock hit a 52-week high of $24.18 and low of $11.41, reflecting significant volatility. Volume surged to 4.5 million shares, well above the 1.6 million daily average, indicating strong investor interest in the analyst rating maintained announcement.

Broader Analyst Coverage

Jefferies raised its price target to $17 from $15, joining five other analysts with Buy ratings. The consensus rating stands at 4.0 out of 5, indicating strong bullish sentiment. No analysts rate the stock as Hold or Sell, showing unified conviction across the research community on SGRY’s prospects.

Healthcare Sector Dynamics and Surgical Facility Trends

Industry Tailwinds

Surgery Partners operates in the medical care facilities sector, benefiting from aging demographics and rising elective procedure volumes. The company’s 126-facility network spans 31 states, providing geographic diversification and scale advantages. Ambulatory surgery centers continue gaining market share from traditional hospital settings due to lower costs and better patient experiences.

Operational Challenges

The company faces headwinds from labor inflation and supply chain pressures affecting margins. Net income per share stands at negative $0.59, reflecting integration costs and one-time charges. However, SGRY’s free cash flow of $1.53 per share demonstrates the underlying business generates cash despite accounting losses, supporting the analyst rating maintained.

Final Thoughts

Jefferies’ decision to maintain its Buy rating while raising the price target to $17 underscores confidence in Surgery Partners’ long-term value creation. The analyst rating maintained reflects belief that current challenges are temporary and that the surgical facility operator will benefit from favorable industry trends. With six Buy ratings and no Sell recommendations, consensus sentiment remains constructive. Investors should monitor upcoming earnings on August 4 for evidence of margin improvement and cash flow acceleration. The B+ Meyka grade and $17 price target suggest meaningful upside potential for patient, long-term investors in the healthcare services space.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.